Watanabe(Y),Takigami(A),Hisata(S),Nakayama... Transl Lung Cancer Res 2026-03-23

...EML4-ALK) fusion variants have been identified, with variants 1-3 (V1-3) accounting for approximately 90% of cases. Howe...

Gu(Z),Chen(Z),Lai(Q),Lin(D) Front Oncol None

...EML4-ALK variant 1 (V1) and variant 3 (V3) showed that V3 was associated with shorter progression-free survival (PFS) in...

Li(S),Du(X),Zhang(X),Ma(H),Yang(Y),Li(Y),W... Transl Cancer Res 2026-03-31

...EML4-ALK fusion, a CDKN2A mutation (p.F90Lfs*30), and 11q13.3 (CCND1, FGF3, FGF4, and FGF19), CDK4, and MDM2 amplificati...

Wu(J),Li(Z),Yang(Z),Liu(C) Transl Lung Cancer Res 2026-02-28

...EML4-ALK rearrangements. The median duration of neoadjuvant therapy was 5 months. The most common treatment-related adve...

Holic(LJ),Trichy(NS),Braat(J),Olivares(S),... Am J Surg Pathol 2026-06-01

...EML4 , were only seen in Spitz melanoma (SM) cases. TERT promoter mutations and c-MYC amplification were only seen in SM...

Gong(J),Zheng(L),Tian(F),Xiao(P),Yu(D),Jia... Front Oncol None

...EML4-ALK fusion, in which targeted therapy demonstrated efficacy. This advanced, unresectable epithelioid angiosarcoma c...

Koo(KM),Kenny(SE),Tan(XNS),Shaon(MA),Farha... ACS Sens 2026-06-26

...EML4-ALK RNA) circulating biomarkers. We successfully validated THANOS's excellent biosensing performance in contrived p...

Kamio(S),Ikegami(M),Kitada(R),Miwa(S),Ogur... J Bone Joint Surg Am 2026-05-27

...EML4::NTRK3. Functional assays suggested their oncogenic potential and demonstrated responsiveness to the TK inhibitors ...

Nie(Y),Staley(A),Hinz(TK),Perez-Johnston(R... Clin Lung Cancer 2026-06-00

...EML4-ALK lung cancer cell lines were engineered to overexpress PD-L1, and effects on ALK TKI response were evaluated in ...

Raphael(A),Peled(N),Gillis(R),Nechushtan(H... Med Sci (Basel) 2026-08-18

...EML4-ALK fusions (n = 2), KIF5B-RET fusion (n = 1), and KRAS p.G12C (n = 1). Targeted-containing regimens achieved rwORR...